FDA
-
-
-
-
-
-
-
Array Biopharma (ARRY) Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial
-
-
-
-
-
-
-
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic C
-
-
-
-
-
-
-
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
-
-
-
-
-
-
-
Array Biopharma (ARRY) Reports Updated Clinical Practice Guidelines from NCCN for BRAFTOVI (encorafenib) in Combination with MEKTOVI (binimetinib) as Category 1 Treatment Option
-
-
-
-
-
-
-
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the
-
-
-
-
-
-
-
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
-
-
-
-
-
-
-
Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal
-
251,865 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All